Related Experiment Video
Updated: May 21, 2026
05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
Molecular imaging of dementia
Takaaki Mori1, Jun Maeda, Hitoshi Shimada
1Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan.
Summary
Positron emission tomography (PET) aids dementia diagnosis by detecting amyloid and tau pathologies. New tracers and targets like Aβ-N3-pyroglutamate enhance early detection and treatment strategies for neurodegenerative diseases.
Area of Science:
- Neuroscience
- Radiochemistry
- Medical Imaging
Background:
- Dementia diagnosis and treatment rely on detecting neuropathological hallmarks.
- Positron emission tomography (PET) is crucial for dementia research, utilizing various radiotracers.
- Early detection of Alzheimer's disease (AD) is vital for effective intervention.
Purpose of the Study:
- To review the role of PET imaging in diagnosing and understanding dementia, particularly Alzheimer's disease.
- To highlight advancements in radiotracers for amyloid and tau imaging.
- To discuss emerging diagnostic and therapeutic targets in dementia.
Main Methods:
- Utilizing various PET tracers, including [(11)C]-6-OH-BTA-1 (Pittsburgh Compound-B) and novel (18)F-labeled ligands for amyloid detection.
- Employing tracers for translocator protein as a biomarker for tau-related toxicity.
- Measuring acetylcholinesterase activity using PET and radiolabeled acetylcholine analogues to assess cholinergic function.
Main Results:
- [(11)C]-6-OH-BTA-1 (Pittsburgh Compound-B) is a widely used PET tracer for amyloid-beta (Aβ) aggregates.
- Newer tracers offer improved sensitivity and longer half-lives for broader clinical use.
- PET imaging can assess tauopathies and cholinergic deficits, aiding differential diagnosis in conditions like Parkinson's disease dementia.
Conclusions:
- PET imaging is essential for both clinical and basic research into prodromal Alzheimer's disease.
- Advancements in radiotracers and identification of targets like Aβ-N3-pyroglutamate improve diagnostic sensitivity.
- Understanding glial roles and cholinergic function through PET complements amyloid and tau imaging for comprehensive dementia assessment.
Related Concept Videos
01:14Brain Imaging
Brain imaging technologies provide critical insights into both the structure and function of the human brain, enabling medical professionals and researchers to diagnose, study, and treat neurological disorders or psychiatric disorders more effectively.
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic Stimulation (TMS).
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic Stimulation (TMS).
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Fundamental Principles of PET
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...